secwatch.observer — SEC 8-K summary
======================================

Issuer:     Organogenesis Holdings Inc. (ORGO)
CIK:        0001661181
Form:       8-K
Filed at:   2023-11-09T23:59:59+00:00
Accession:  0000950170-23-062041
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Organogenesis Q3 revenue down 7% to $108.5M; net income rises to $3.2M; guides FY rev down 1-4%
--------------------------------------------------------------------------------

- Net revenue $108.5M, down $8.3M YoY; Advanced Wound Care fell 7% to $101.4M; Surgical & Sports Med fell 2% to $7.2M.
- Net income $3.2M ($0.02/sh) vs $0.2M ($0.00/sh) in Q3 2022; adjusted net income $5.3M vs $5.1M.
- Adjusted EBITDA $16.0M, up 38% from $11.6M; operating income $8.1M vs $1.8M.
- FY2023 guidance: net revenue $433-446M (down 1-4% YoY); net income $4-9M; adjusted net income $11-17M.
- Revenue impacted by LCD withdrawal issues; profitability improved despite headwinds.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1661181/000095017023062041/0000950170-23-062041-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1661181/000095017023062041/orgo-20231109.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-062041

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer